What does a 70% hemoglobin S (HbS) level on high‑performance liquid chromatography indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

HbS 70% on HPLC: Diagnostic Interpretation

A hemoglobin S level of 70% on HPLC most likely indicates sickle β⁺-thalassemia (HbS/β⁺-thal) compound heterozygosity, though homozygous sickle cell disease (HbSS) remains possible if the patient has recently been transfused or has elevated fetal hemoglobin.

Understanding the HbS Percentage

The 70% HbS level falls into a diagnostic gray zone that requires careful interpretation:

Most Likely Diagnosis: HbS/β⁺-Thalassemia

  • Expected HbS range: 70-80% 111
  • The presence of residual HbA (typically 10-25%) distinguishes this from HbSS 1
  • This genotype is associated with mild disease severity compared to HbSS 11
  • Patients typically have higher baseline hemoglobin than HbSS (not the severe anemia of 60-90 g/L seen in HbSS) 11

Alternative Consideration: HbSS Disease

  • Expected HbS range: 80-95% 111
  • Associated with severe disease phenotype 11
  • Baseline hemoglobin typically 60-90 g/L 11
  • A 70% HbS in HbSS could occur if:
    • Patient has elevated HbF (>8%), which offers protection and reduces HbS percentage 11
    • Patient is on hydroxycarbamide therapy (raises HbF levels) 11
    • Recent blood transfusion has diluted the HbS percentage 2

Less Likely: HbS/β⁰-Thalassemia

  • Expected HbS: 80-90% 1
  • No HbA present (key distinguishing feature) 1
  • Severe disease phenotype 1

Critical Next Steps for Definitive Diagnosis

Review the complete HPLC report for:

  1. HbA percentage:

    • If HbA present (10-25%) → confirms HbS/β⁺-thal 1
    • If HbA absent (0%) → suggests HbSS or HbS/β⁰-thal 1
  2. HbF level:

    • 8% suggests milder phenotype regardless of genotype 11

    • Very high HbF (>15%) in HbSS may explain lower HbS percentage 1
  3. HbA2 level:

    • Elevated (>3.9%) supports β-thalassemia trait component 34
    • Important caveat: HbS-containing samples show falsely elevated HbA2 on HPLC (mean 4.09% in HbAS trait vs 2.57% in normal) 2
  4. Red cell indices from CBC:

    • Severe microcytosis (MCV <70 fL) with high RBC count favors thalassemia component 15
    • Mild anemia with normal MCV suggests HbSS with high HbF 1

Clinical Severity Assessment

The clinical phenotype matters more than the exact genotype for management:

  • HbS/β⁺-thal (70-80% HbS): Mild phenotype, fewer painful crises, higher baseline Hb 11
  • HbSS (80-95% HbS): Severe phenotype, early painful crises, severe anemia (Hb 60-90 g/L) 11

Key clinical discriminators:

  • Age of symptom onset (early in HbSS, later in HbS/β⁺-thal)
  • Frequency of painful crises
  • Baseline hemoglobin level
  • History of acute chest syndrome or stroke
  • Transfusion history

Management Implications

For perioperative planning (if relevant):

  • Preoperative transfusion targets are individualized based on:

    • Baseline hemoglobin (<9 g/dL requires simple transfusion) 6
    • Surgery risk level (high-risk surgery may require exchange transfusion to HbS <30%) 61
    • Target post-transfusion Hb: 9-11 g/dL (not >11 g/dL to avoid hyperviscosity) 6
  • HbS/β⁺-thal patients may require exchange transfusion rather than simple transfusion if baseline Hb is already elevated, to avoid hyperviscosity 1

Common Pitfalls to Avoid

  1. Don't rely solely on HbS percentage for diagnosis—always correlate with HbA presence, clinical phenotype, and family history 72

  2. Recent transfusion can dramatically alter HPLC results—check transfusion history within past 3 months 12

  3. HbA2 elevation in HbS-containing samples is an artifact of HPLC methodology, not necessarily indicative of β-thalassemia trait 2

  4. Molecular genetic testing is definitive when phenotypic results are ambiguous 87

Recommend molecular genetic testing if: clinical severity doesn't match expected genotype, family planning is being considered, or HPLC pattern is atypical 87.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.